SCHEMBL23612445

SCHEMBL23612445

CC(C)c1ccc2c(c1)/C(=N\O)C(=O)N2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.46
GFER P55789 1/20 0.46
HSD17B10 Q99714 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.40
EGFR P00533 1/20 0.40
ERBB2 P04626 1/20 0.40
IGF1R P08069 1/20 0.40
PDGFRB P09619 1/20 0.40
GLB1 P16278 1/20 0.40
CTRC Q99895 1/20 0.40
MAPT P10636 2/20 0.40
LMNA P02545 2/20 0.40
AGTR1 P30556 1/20 0.40
TRPA1 O75762 1/20 0.40
PTGS1 P23219 1/20 0.40
CACNA1C Q13936 1/20 0.40
LRRK2 Q5S007 4/20 0.37
TP53 P04637 1/20 0.37
MDM2 Q00987 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23612442 0.84 HPGD (0.46) HPGDGFERHSD17B10SMN1; SMN2EGFR
SCHEMBL6325239 0.79 MAPT (0.60) SMN1; SMN2PDGFRBMAPTLMNAAGTR1
SCHEMBL6325243 0.79 MAPT (0.60) SMN1; SMN2PDGFRBMAPTLMNAAGTR1
SCHEMBL20436331 0.79 MAPT (0.60) SMN1; SMN2PDGFRBMAPTLMNAAGTR1
SCHEMBL4444879 0.78 TGM2 (0.55) HPGDGFERHSD17B10EGFRERBB2
SCHEMBL23612447 0.76 HPGD (0.47) HPGDGFERHSD17B10EGFRERBB2
SCHEMBL30813240 0.76 LRRK2 (0.60) AGTR1LRRK2
SCHEMBL6315587 0.76 TGM2 (0.61) MAPTAGTR1LRRK2
SCHEMBL2707210 0.76 ACVR1 (0.51) HPGDGFERHSD17B10SMN1; SMN2EGFR
SCHEMBL7220775 0.76 SMN1; SMN2 (0.40) SMN1; SMN2MAPTLMNAAGTR1LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11052092-B2 N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases GENFIT (FR) 2021-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11052092-B2 N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases RORA, RORC, RORB HPGD 1037/4885GFER 3887/4885HSD17B10 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.